Anti-Neprilysin Drug Market Size - By Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), By Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) & By Region: Global Forecast 2023 - 2033

<p>Anti-Neprilysin Drug Market is projected to reach USD 2,183M by 2033 with a CAGR of 4.9% from 2023 to 2033 segmented into type, indication, distribution channel and region.</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Description</td></tr><tr><th scope='row'>Market Size in 2022</th><td>USD 1,034 Million</td></tr><tr><th scope='row'>Market Forecast in 2033</th><td>USD 2,183 Million</td></tr><tr><th scope='row'>CAGR % 2023-2033</th><td>4.9%</td></tr><tr><th scope='row'>Base Year</th><td>2022</td></tr> <tr><th scope='row'>Historic Data</th><td>2016-2022</td></tr> <tr><th scope='row'>Forecast Period</th><td>2023-2033</td></tr><tr><th scope='row'>Report USP</th><td>Production, Consumption, company share, company heatmap, company production capacity, growth factors and more</td></tr><tr><th scope='row'>Segments Covered</th><td>by Drug Type, by Indication, by Distribution Channel</td></tr><tr><th scope='row'>Growth Drivers</th><td>Increasing Prevalence of Heart Failure Anti-neprilysin drugs are often used in combination with angiotensin receptor blockers (ARBs) to enhance their effectiveness. Ongoing research and development in the pharmaceutical industry have led to the discovery and development of new anti-neprilysin drugs, expanding the available options.</td></tr><tr><th scope='row'>Regional Scope</th><td>North America, Europe, APAC, South America and Middle East and Africa</td></tr> <tr><th scope='row'>Country Scope</th><td>U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria</td></tr> <tr><th scope='row'>Key Companies</th><td>Novartis AG, BIOPROJET, Pharmaleads SA, Cipla Inc, Oceanic Pharmachem Pvt. Ltd., Theravance Biopharm.</td></tr></tbody></table>

<p>抗中性粒细胞蛋白酶药物市场预计将在2033年达到21.83亿美元，年复合增长率(CAGR)为4.9%，市场按类型、适应症、分销渠道和地区进行细分。</p><table><tbody><tr><th scope='row'>报告属性</th><td>描述</td></tr><tr><th scope='row'>2022年市场规模</th><td>10.34亿美元</td></tr><tr><th scope='row'>2033年市场预测</th><td>21.83亿美元</td></tr><tr><th scope='row'>2023-2033年CAGR百分比</th><td>4.9%</td></tr><tr><th scope='row'>基准年份</th><td>2022年</td></tr><tr><th scope='row'>历史数据</th><td>2016-2022年</td></tr><tr><th scope='row'>预测期间</th><td>2023-2033年</td></tr><tr><th scope='row'>报告独特卖点</th><td>生产、消费、公司市场份额、公司热点图、公司生产能力、增长因素等</td></tr><tr><th scope='row'>涵盖的细分市场</th><td>按药物类型、按适应症、按分销渠道</td></tr><tr><th scope='row'>增长动力</th><td>心力衰竭的发病率上升。抗中性粒细胞蛋白酶药物常与血管紧张素受体阻滞剂(ARBs)联合使用以增强其疗效。制药行业的持续研发活动导致了新型抗中性粒细胞蛋白酶药物的发现和开发，从而扩大了可用药物的选择范围。</td></tr><tr><th scope='row'>区域范围</th><td>北美、欧洲、亚太地区、南美洲以及中东和非洲</td></tr><tr><th scope='row'>国家范围</th><td>美国；加拿大；英国；德国；法国；意大利；西班牙；比荷卢；北欧国家；俄罗斯；中国；印度；日本；韩国；澳大利亚；印度尼西亚；泰国；墨西哥；巴西；阿根廷；沙特阿拉伯；阿联酋；埃及；南非；尼日利亚</td></tr><tr><th scope='row'>主要公司</th><td>诺华制药有限公司，BIOPROJET，Pharmaleads SA，Cipla Inc，Oceanic Pharmachem Pvt. Ltd.，Theravance Biopharm。</td></tr></tbody></table>